Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.

ABSTRACT:

Background

High-risk neuroblastoma patients with end-induction residual disease commonly receive post-induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to investigate the efficacy of this approach.

Methods

Patients diagnosed between 2008 and 2018 without progressive disease with a partial response or worse at end-induction were stratified according to the post-induction treatment: 1) no additional therapy before ASCT (cohort 1), 2) post-induction "bridge" therapy before ASCT (cohort 2), and 3) post-induction therapy without ASCT (cohort 3). χ² tests were used to compare patient characteristics. Three-year event-free survival (EFS

SUBMITTER: Desai AV 

PROVIDER: S-EPMC10764281 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature